Register
Login:
Share:
Email Facebook Twitter

VIDEO EXCLUSIVE: Coinsilium & Kryptonite1 - the only-UK listed Blockchain and Token Economy CEO's explain how to spread your risk. Watch here

EXCLUSIVE: Video presentations from MySQUAR, My Pay, Consilium and Kryptonite1 are now available here


Regulatory News


Notice of Results

Wed, 27th Sep 2017 09:00


RNS Number : 9454R
SkinBioTherapeutics PLC
27 September 2017
 

SkinBioTherapeutics plc

 

Notice of full year results

 

Manchester, UK - 27 September 2017 - SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life science company focused on skin health, will publish its full year results for the year to 30 June 2017 on Thursday, 5 October 2017.

-Ends-

 

For more information, please contact:

SkinBioTherapeutics plc

Dr. Cath O'Neill, CEO

Doug Quinn, CFO

 

Tel: +44 (0) 161 468 2760

Cairn Financial Advisers LLP

Tony Rawlinson / Emma Earl / Richard Nash

 

Tel: +44 (0) 20 7213 0880

Turner Pope Investments

Ben Turner / James Pope

 

Tel: +44 (0) 20 3621 4120

 

Instinctif Partners

Melanie Toyne-Sewell / Deborah Bell

 

Tel: +44 (0) 20 7457 2020

SkinBio@instinctif.com

 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.

SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin.  The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models.  Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. 

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).

The Company joined AIM in April 2017 concurrent with raising £4.5 million from a placing of new ordinary shares.

The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORGRGDCLUDBGRR





Back to Regulatory News


Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk




Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.